Holen Sie sich die Stockscreener-App
110.65
2.67%
-3.29
Schlusskurs vom Vortag:
$113.94
Offen:
$112.85
24-Stunden-Volumen:
126.86K
Relative Volume:
0.58
Marktkapitalisierung:
$741.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.99M
KGV:
-53.54
EPS:
-2.0665
Netto-Cashflow:
$-10.01M
1W Leistung:
+2.95%
1M Leistung:
+1.66%
6M Leistung:
+102.35%
1J Leistung:
+207.54%
1-Tages-Spanne:
$109.14
$112.86
1-Wochen-Bereich:
$104.48
$117.50
52-Wochen-Spanne:
$32.77
$124.82
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
110.54 | 744.25M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
542.68 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.37 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,028.30 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.03 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.55 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-09-09 | Eingeleitet | BTIG Research | Buy |
| 2025-09-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-08-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-19 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-10 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
MNPR drops as short-term selling pressure persists - Traders Union
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $130 - Moomoo
What's behind Monopar Therapeutics's latest stock pullback? - Traders Union
Monopar (MNPR) Chart: Retreats 2.41% to $120.85 in the Latest Reading; Price Levels: $114.81 and $126.89 Define the Nearby Reference Levels under the Current SnapshotLeveraged ETF Flow - vinanet.vn
Monopar appoints medical affairs head, presents at liver meeting By Investing.com - Investing.com South Africa
Monopar appoints medical affairs head, presents at liver meeting - Investing.com
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLDThe Liver Meeting® 2026 - The Manila Times
Monopar (MNPR) Price Update: Rises 1.94% to $118.75 at the Close; Price Context: the $112.81 to $124.69 Range Remains in Focus in the Latest ReadingLate Stage Breakouts - vinanet.vn
Monopar: Licensing Agreement, Rolling NDA Submission Serve As Catalysts For ‘Strong Buy’ - Seeking Alpha
(MNPR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen - MarketBeat
Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold - MarketBeat
Equities Analysts Offer Predictions for MNPR FY2029 Earnings - MarketBeat
Buy Rating Reiterated on Monopar as ALXN-1840 Advances in Wilson Disease; $125 Price Target Maintained - TipRanks
Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald - marketscreener.com
Monopar downgraded to Neutral at Cantor (MNPR:NASDAQ) - Seeking Alpha
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
MNPR Maintained by Barclays -- Price Target Raised to $128.00 - GuruFocus
MNPR Downgraded by Cantor Fitzgerald -- Price Target Raised to $119 - GuruFocus
Monopar Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Cantor downgrades Monopar stock on valuation after 90% rally - Investing.com
Cantor downgrades Monopar stock on valuation after 90% rally By Investing.com - Investing.com Canada
MONOPAR THERAPEUTICS INC. : BTIG RAISES TARGET PRICE TO $133 FROM $117 - Bitget
Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile - TipRanks
Saturn V Capital shows sub-5% Monopar Therapeutics (MNPR) stake in 13G/A - Stock Titan
Monopar Therapeutics stock price target raised to $133 by BTIG - Investing.com Canada
MNPR Maintained by BTIG -- Price Target Raised to $133 - GuruFocus
BTIG Research Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Adage Capital discloses 4.76% Monopar Therapeutics (MNPR) stake including warrants - Stock Titan
Form 8K Monopar Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Monopar Therapeutics' Q2 Net Loss Widens - marketscreener.com
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update on ALXN1840 NDA Submission - Quiver Quantitative
Monopar Reports Q2 2026 Net Loss of $5.3 Million - Quiver Quantitative
Monopar Therapeutics reports Q2 2026: $5.3M net loss, $134.3M cash on hand - TradingView
Monopar Therapeutics 2Q 2026: Net income $(5.31M), EPS $(0.62) — 10-Q Summary - TradingView
Monopar Therapeutics (MNPR) deepens R&D spend but retains $134M cash runway - Stock Titan
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen - MarketBeat
Monopar Therapeutics Inc. expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Bank of New York Mellon Corp Has $4.31 Million Position in Monopar Therapeutics Inc. $MNPR - MarketBeat
Why is Monopar Therapeutics stock up today? Resistance levels in focus - tradersunion.com
Monopar Therapeutics (NASDAQ:MNPR) Sets New 1-Year HighWhat's Next? - marketbeat.com
MNPR Q2'26 Earnings: EPS estimate is (0.66) USD - TradingView
Monopar Therapeutics stock approaches $125.77 resistance as bullish momentum drives gains - Traders Union
Monopar Therapeutics (MNPR) Projected to Post Earnings on Tuesday - MarketBeat
Monopar Therapeutics stock closes near session high as buyers regain control - tradersunion.com
Monopar Therapeutics (MNPR) Gains 3% as Stock Holds Above Key SupportInvestment Factor - vinanet.vn
MNPR Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Pipeline Progress ContinuesEarnings Season Outlook - vinanet.vn
Monopar Therapeutics (MNPR) Slides 5.5% as Biotech Stock Tests Key Support at $102.93Relative Volume - vinanet.vn
Why is Monopar Therapeutics stock down today? Key support levels to watch - Traders Union
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Monopar Therapeutics Inc-Aktie (MNPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RIOUX PATRICE | Acting Chief Medical Officer |
Aug 26 '26 |
Sale |
111.26 |
1 |
111 |
5,065 |
| Tsuchimoto Kim R | Director |
Aug 26 '26 |
Sale |
111.39 |
4,090 |
455,567 |
7,396 |
| Anderson Raymond | Director |
Aug 25 '26 |
Sale |
111.77 |
3,142 |
351,189 |
23,751 |
7.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):